Bayer acquires Icon Genetics AG
The acquisition will strengthen Bayer's activities aimed at producing specific pharmaceutical substances in plants (plant-made pharmaceuticals, or PMPs). This technology utilizes the natural protein production processes in plants as a way of producing therapeutically active substances. The parties have agreed not to disclose any details of the acquisition. Closing of the transaction took place on January 9, 2006.
Most read news
Other news from the department business & finance
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.